PSMB8 and autoimmune thrombocytopenic purpura: Our results suggest that the immunoproteasome may play a pathogenic role in ITP, and demonstrate that the co-inhibition of LMP2 and LMP7 is a novel potential therapeutic strategy for the treatment of ITP.